Coulter IPO generates $30 mil.; B-1 therapy NDA slated for filing in mid/late 1998.
Executive Summary
COULTER B-1 THERAPY STUDIES IN RELAPSED LOW-GRADE 39424NON-HODGKIN'S LYMPHOMA patients are slated to begin this year, the Coulter Corp. spin-off said in a preliminary prospectus for its initial public offering. "To broaden the label indication, the company plans to carry out a randomized, controlled Phase III/IV clinical trial in patients with low-grade or transformed low-grade NHL in first or second relapse," the prospectus states. "The company currently plans to commence this clinical trial during the second half of 1997."